A Phase 2 interventional study of Efinopegdutide in Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 39 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 in phase 2, and was the 11th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 113 across the 10 interventional studies, 10 across the 1 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive efinopegdutide Q1W via subcutaneous (SC) injection for 28 weeks in a dose-escalating regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for up to 16 weeks.
Drug: Efinopegdutide
Participants will receive efinopegdutide Q2W via SC injection for 28 weeks in a dose-escalating regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for up to 16 weeks.
Drug: Efinopegdutide
Participants will receive efinopegdutide Q2W via SC injection for 28 weeks in a dose-escalating regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, 10 mg for 4 weeks, and 15 mg for up to 12 weeks.
Drug: Efinopegdutide
SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm
Also known as: MK-6024, HM12525A, JNJ-64565111
Mean Relative Reduction From Baseline in Liver Fat Content at Week 28
Liver fat content (LFC) was measured with liver images taken by magnetic resonance imaging estimated proton density fat fraction (MRI-PDFF) and analyzed by blinded independent central review (BICR). Relative Reduction from Baseline to Week 28 = (Baseline - Week 28) / Baseline x 100%. Least Squares (LS) Mean relative reduction from baseline in LFC is presented.
Time frame: Baseline and Week 28
Percentage of Participants Who Experienced an Adverse Event (AE)
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who experienced an AE is presented.
Time frame: Up to Week 32
Percentage of Participants Who Discontinued Study Intervention Due to an AE
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who discontinued study intervention due to an AE is presented.
Time frame: Up to Week 28
Mean Percent Change From Baseline in Body Weight at Week 28
Body weight in kilograms was measured using a standardized, digital scale. Mean percent change in body weight from Baseline to Week 28 = (Week 28 - Baseline) / Baseline x 100%. The LS mean percent change from baseline in body weight at 28 weeks is presented.
Time frame: Baseline and Week 28
| Milestone | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg |
|---|---|---|---|
| Started | 42 | 40 | 42 |
| Treated | 42 | 39 | 42 |
| Completed | 39 | 35 | 34 |
| Not completed | 3 | 5 | 8 |
| Withdrew: Exclusionary laboratory result | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 4 |
| Withdrew: Physician decision | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 3 |
Liver fat content (LFC) was measured with liver images taken by magnetic resonance imaging estimated proton density fat fraction (MRI-PDFF) and analyzed by blinded independent central review (BICR). Relative Reduction from Baseline to Week 28 = (Baseline - Week 28) / Baseline x 100%. Least Squares (LS) Mean relative reduction from baseline in LFC is presented.
| Percent Reduction | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg |
|---|---|---|---|
| Mean Relative Reduction From Baseline in Liver Fat Content at Week 28 | 67.8 (60.7 to 74.9) | 54.4 (46.8 to 61.9) | 42.1 (34.6 to 49.5) |
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who experienced an AE is presented.
| Percentage of participants | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg |
|---|---|---|---|
| Percentage of Participants Who Experienced an Adverse Event (AE) | 83.3 | 82.1 | 85.7 |
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who discontinued study intervention due to an AE is presented.
| Percentage of participants | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg |
|---|---|---|---|
| Percentage of Participants Who Discontinued Study Intervention Due to an AE | 7.1 | 5.1 | 9.5 |
Body weight in kilograms was measured using a standardized, digital scale. Mean percent change in body weight from Baseline to Week 28 = (Week 28 - Baseline) / Baseline x 100%. The LS mean percent change from baseline in body weight at 28 weeks is presented.
| Percent Change | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg |
|---|---|---|---|
| Mean Percent Change From Baseline in Body Weight at Week 28 | -7.5 (-8.8 to -6.1) | -3.9 (-5.3 to -2.5) | -4.1 (-5.5 to -2.7) |
Collected over Up to Week 32. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efinopegdutide Q1W 10 mg | 0/42 (0%) | 3/42 (7.1%) | 30/42 (71.4%) |
| Efinopegdutide Q2W 10 mg | 0/40 (0%) | 2/39 (5.1%) | 27/39 (69.2%) |
| Efinopegdutide Q2W 15 mg | 0/42 (0%) | 4/42 (9.5%) | 33/42 (78.6%) |
| Event | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg |
|---|---|---|---|
| Ankle fractureInjury, poisoning and procedural complications | 1/42 | 1/39 | 0/42 |
| Lumbar radiculopathyNervous system disorders | 0/42 | 1/39 | 0/42 |
| Supraventricular tachycardiaCardiac disorders | 0/42 | 0/39 | 1/42 |
| VomitingGastrointestinal disorders | 1/42 | 0/39 | 0/42 |
| AppendicitisInfections and infestations | 0/42 | 0/39 | 1/42 |
| BacteraemiaInfections and infestations | 0/42 | 0/39 | 1/42 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/42 | 0/39 | 0/42 |
| CholecystitisHepatobiliary disorders | 0/42 | 0/39 | 1/42 |
| Event | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 14/42 | 13/39 | 20/42 |
| ConstipationGastrointestinal disorders | 11/42 | 8/39 | 12/42 |
| DiarrhoeaGastrointestinal disorders | 9/42 | 3/39 | 6/42 |
| VomitingGastrointestinal disorders | 8/42 | 7/39 | 9/42 |
| HeadacheNervous system disorders | 9/42 | 2/39 | 5/42 |
| Injection site painGeneral disorders | 5/42 | 1/39 | 8/42 |
| Decreased appetiteMetabolism and nutrition disorders | 7/42 | 6/39 | 5/42 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 6/42 | 1/39 | 4/42 |
| DizzinessNervous system disorders | 2/42 | 1/39 | 6/42 |
| Abdominal distensionGastrointestinal disorders | 5/42 | 0/39 | 1/42 |
All randomized participants.
| Age, Continuous(years) | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg | Total |
|---|---|---|---|---|
| Mean | 47.6 ± 11.9 | 53.4 ± 12.6 | 50.8 ± 13.8 | 50.6 ± 12.9 |
| Sex: Female, Male(Participants) | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg | Total |
|---|---|---|---|---|
| Female | 27 | 22 | 28 | 77 |
| Male | 15 | 18 | 14 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 28 | 23 | 28 | 79 |
| Not Hispanic or Latino | 14 | 17 | 13 | 44 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 3 | 4 | 11 |
| White | 37 | 32 | 38 | 107 |
| More than one race | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 0 | 2 | 0 | 2 |
| Weight(kg) | Efinopegdutide Q1W 10 mg | Efinopegdutide Q2W 10 mg | Efinopegdutide Q2W 15 mg | Total |
|---|---|---|---|---|
| Mean | 105.5 ± 21.2 | 108.4 ± 24.4 | 101.8 ± 20.7 | 105.2 ± 22.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jul 2024 to primary completion in Jun 2025, 10 months.
Results were first posted in Jun 2026, 11 months after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 10 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efinopegdutide
Non-alcoholic Fatty Liver Disease →